re - Not good for the potential of apabetalone as a Covid-19
not sure Bear looks at stockhouse any longer, but he just posted this on agoracommie
https://agoracom.com/ir/Resverlogix/forums/discussion/topics/770557-not-good-for-the-potential-of-apabetalone-as-a-covid-19-therapy/messages/2338952#message
wondering about the significance of this... a couple things caught my eye in the abstract he posted:
in the Summary section there is this line "Knockouts of BRD3 or BRD4 in cells overexpressing ACE2 exacerbate SARS-CoV-2 infection; "
and in the discussion portion this: "Because most BET inhibitors do not distinguish between the different BET proteins and inhibit all of them indiscriminately, our study urges caution with the clinical use, prophylactic or therapeutic, of pan-BET inhibitors in people at risk or afflicted with COVID-19."
that doesn't jive w/ my understanding:
thought we were NOT a pan-BET inhibitor?
thought we hit BRD4, not both BRD3 and BRD4? or was it BRD2 and not both BRD3 and BRD4?
am i missing something? maybe someone can ask Bear on agora? i would think this would be *good* for us?!
maybe that's why we languish....
thx.....